HCWB · HCW Biologics Inc.

The amendment to HCW Biologics’ Bylaws modifies a foundational procedural threshold for shareholder meetings: the quorum requirement. By reducing the quorum from a majority to one-third of voting power, the Company lowers the bar for conducting official business at shareholder meetings, which may facilitate faster decision-making on routine or urgent matters. This change does not alter voting thresholds for specific proposals (e.g., director elections or charter amendments), which remain subject to separate vote requirements under Delaware law and the Bylaws. The effective date of April 28, 2026—13 days after Board approval—suggests administrative or notice-related timing considerations, though the filing does not specify whether shareholder notice or regulatory filings triggered the delay. As a governance adjustment rather than a financial, operational, or strategic event, the amendment carries procedural significance but no direct impact on capital structure, operations, or executive leadership. Investors should note that reduced quorum thresholds can influence shareholder engagement dynamics, particularly in companies with dispersed ownership or low meeting attendance, though no related disclosures about ownership concentration or historical quorum challenges are provided.